Old Web
English
Sign In
Acemap
>
Paper
>
PS-3Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC
PS-3Japan subset of Phase III study KEYNOTE-024: Pembrolizumab for PD-L1 TPS > =50%, treatment-naïve NSCLC
2017
Miyako Satouchi
Katsuyuki Hotta
Kaname Nosaki
Toshiaki Takahashi
Kazuhiko Nakagawa
Keisuke Aoe
Kazuo Noguchi
Takashi Shimamoto
Reshma Rangwala
Julie R. Brahmer
Keywords:
General surgery
Medicine
PD-L1
Cancer research
Pembrolizumab
therapy naive
Oncology
Internal medicine
Pathology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
1
Citations
NaN
KQI
[]